134 related articles for article (PubMed ID: 11137651)
1. Survival of Stenotrophomonas maltophilia following exposure to concentrations of tobramycin used in aerosolized therapy for cystic fibrosis patients.
Mooney L; Kerr KG; Denton M
Int J Antimicrob Agents; 2001 Jan; 17(1):63-6. PubMed ID: 11137651
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Law JP; Wood AJ; Friman VP
Microbiol Spectr; 2022 Dec; 10(6):e0184222. PubMed ID: 36453898
[TBL] [Abstract][Full Text] [Related]
3. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.
Ratjen A; Yau Y; Wettlaufer J; Matukas L; Zlosnik JE; Speert DP; LiPuma JJ; Tullis E; Waters V
Antimicrob Agents Chemother; 2015 Jan; 59(1):711-3. PubMed ID: 25348526
[TBL] [Abstract][Full Text] [Related]
4. Microbiological and immunologic considerations with aerosolized drug delivery.
LiPuma JJ
Chest; 2001 Sep; 120(3 Suppl):118S-123S. PubMed ID: 11555566
[TBL] [Abstract][Full Text] [Related]
5. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.
Schülin T
J Antimicrob Chemother; 2002 Feb; 49(2):403-6. PubMed ID: 11815589
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates.
Cantón R; Valdezate S; Vindel A; Sánchez Del Saz B; Maíz L; Baquero F
Pediatr Pulmonol; 2003 Feb; 35(2):99-107. PubMed ID: 12526070
[TBL] [Abstract][Full Text] [Related]
8. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
Saiman L; Chen Y; Gabriel PS; Knirsch C
Antimicrob Agents Chemother; 2002 Apr; 46(4):1105-7. PubMed ID: 11897598
[TBL] [Abstract][Full Text] [Related]
9. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.
Wu K; Yau YC; Matukas L; Waters V
Antimicrob Agents Chemother; 2013 Mar; 57(3):1546-8. PubMed ID: 23295930
[TBL] [Abstract][Full Text] [Related]
10. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia.
Pompilio A; Crocetta V; Scocchi M; Pomponio S; Di Vincenzo V; Mardirossian M; Gherardi G; Fiscarelli E; Dicuonzo G; Gennaro R; Di Bonaventura G
BMC Microbiol; 2012 Jul; 12():145. PubMed ID: 22823964
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients.
Pompilio A; Scocchi M; Pomponio S; Guida F; Di Primio A; Fiscarelli E; Gennaro R; Di Bonaventura G
Peptides; 2011 Sep; 32(9):1807-14. PubMed ID: 21849157
[TBL] [Abstract][Full Text] [Related]
12. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
13. Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients.
Nazik H; Ongen B; Erturan Z; Salcioğlu M
Jpn J Infect Dis; 2007 May; 60(2-3):82-6. PubMed ID: 17515637
[TBL] [Abstract][Full Text] [Related]
14. Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis.
Denton M; Rajgopal A; Mooney L; Qureshi A; Kerr KG; Keer V; Pollard K; Peckham DG; Conway SP
J Hosp Infect; 2003 Nov; 55(3):180-3. PubMed ID: 14572484
[TBL] [Abstract][Full Text] [Related]
15. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
Mathy V; Grohs P; Compain F
J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
[TBL] [Abstract][Full Text] [Related]
17.
Willsey GG; Eckstrom K; LaBauve AE; Hinkel LA; Schutz K; Meagher RJ; LiPuma JJ; Wargo MJ
J Bacteriol; 2019 Aug; 201(15):. PubMed ID: 31109991
[No Abstract] [Full Text] [Related]
18. Genomic information on Stenotrophomonas maltophilia ST264 isolated from a cystic fibrosis pediatric patient in Brazil.
Braga FS; D'Allincourt Carvalho Assef AP; Leão RS; Albano RM; Marques EA
Braz J Microbiol; 2020 Sep; 51(3):1125-1127. PubMed ID: 31858443
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
[TBL] [Abstract][Full Text] [Related]
20. Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.
Farfour E; Trochu E; Devin C; Cardot Martin E; Limousin L; Roux A; Picard C; Jolly E; Vasse M; Lesprit P
Transpl Infect Dis; 2018 Oct; 20(5):e12955. PubMed ID: 29896802
[No Abstract] [Full Text] [Related]
[Next] [New Search]
